Clinical Trials Browser

Phase 1 × ASTX-660 × Clear all

NCT05403450 2026-02-23

A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)

Phase 1 Active not recruiting

Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Peripheral

NCT05082259 2026-02-10

ASTEROID

Phase 1 Recruiting

BreastGynecologic

Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms

NCT06590558 2025-07-03

Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer

Phase 1 Withdrawn

Triple Negative Breast Neoplasms

NCT04155580 2024-08-02

A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Phase 1 Terminated

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT05912075 2024-02-08

PRAAR1

Phase 1 Recruiting

Gastrointestinal

Locally-advanced Rectal Cancer